Four Later-Stage Immunotherapy Strategies Appear Promising

Anita T. Shaffer @Shaffer1
Published: Thursday, Jun 14, 2012
Dr. Leonard Gomella

Jeffrey Holmes Photography

Leonard G. Gomella, MD, discusses immunotherapy.

While many approaches to using immunotherapy for the treatment of prostate cancer are under study, four strategies currently in later-stage clinical development have emerged as the most promising advances in the field thus far, according to Leonard G. Gomella, MD.

These agents are coming into focus at a time when immunotherapy is an increasingly accepted approach to the treatment of prostate cancer. Gomella anticipates that new immunotherapies will become available in the next several years, and that treatment issues will increasingly focus on how to combine and sequence modalities.

Gomella, who served as a program director for the IPCC conference, is chair of the Department of Urology and director of Clinical Affairs at the Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

He said that prostate cancer makes a good target for immunotherapy for several reasons, including a slowgrowing nature that gives the patient’s immune system time to generate a response and the multiple tissue-specific proteins that could serve as prostate tumor antigens.

“We did come over a hurdle about 10 years ago in prostate cancer, realizing from a molecular standpoint and from a proteomic and immunologic standpoint that you could stimulate the immune system to recognize prostate cells or turn on the immune system in order to fight advanced prostate cancer,” Gomella said in an interview during IPCC. “All these things are very exciting and I think where we’re going to be looking at all these immunotherapeutic agents in the next five years will concern sequencing.”

He identified studies involving these agents as the most noteworthy (Table):

  • Sipuleucel-T (Provenge; Dendreon)—The therapeutic vaccine, which the FDA has approved for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC), is being investigated for earlier-stage disease. The vaccine is custom-manufactured for each patient by harvesting his antigen-presenting cells (APCs) through leukapheresis and culturing the APCs with immune-stimulating cells. The activated APCs are then infused into the patient. The process is repeated three times.
  • PROSTVAC (Bavarian Nordic)—The vaccine, which relies upon pox viral vectors to stimulate the immune system, is under study in mCRPC. PROSTVAC is a sequentially dosed combination of two poxviruses, Vaccinia and Fowlpox, each encoded with prostate-specific antigen (PSA) plus TRICOM (three costimulatory molecules [B7.1, ICAM-1, and Lfa-3]). The first poxvirus is Vaccinia- PSA-TRICOM; the second is Fowlpox-PSA-TRICOM.
  • Ipilimumab (Yervoy; Bristol-Myers Squibb)—The monoclonal antibody, which the FDA approved for the treatment of unresectable or metastatic melanoma last year, is under evaluation for patients with CRPC who have received radiotherapy and docetaxel. Ipilimumab employs a checkpoint blockade strategy that maintains activated tumor-specific T-cells by neutralizing CTLA4, a coinhibitory receptor.
  • 177Lu-J591 (Weill Cornell Medical College)—The radiolabeled monoclonal antibody is being tested in combination with ketoconazole plus hydrocortisone in high-risk patients whose disease has relapsed biochemically after local therapy. 177Lu-J591 binds to prostate-specific membrane antigens, which are expressed on virtually all prostate cancer cells, and triggers antibody-dependent cell-mediated cytotoxicity.

Table. Ongoing Immunotherapy Trials

Study Phase Study Population Treatment Arms Endpoints Sponsor
PROTECT
P-11
(NCT00779402)
III Nonmetastatic
ADPC
3 mo ADT + sipuleucel-T
vs
3 mo ADT + control
BF, DF, OS, PSADT Dendreon
NeoACT
P07-1
(NCT00715104)
II Localized PC Sipuleucel-T x 3 prior to RP + post-op booster vs Sipuleucel-T x 3 prior to RP + no booster Immune response, safety Dendreon
ProACT
P07-2
(NCT00715078)
II Asymptomatic or minimally symptomatic CRPC Sipuleucel-T at 3 different concentrations of PA2024 antigens CD54 upregulation, immune response, OS Dendreon
177Lu-J591
(NCT00859781)
II High-risk, nonmetastatic CRPC 177Lu-J591 + ketoconazole + hydrocortisone vs 111In-J591 (placebo) + ketoconazole + hydrocortisone PFS, OS, PSA, RECIST Weill Cornell Medical College
Ipilimumab (NCT00861614) III CRPC post docetaxel XRT + ipilumumab vs XRT + placebo OS, PFS, pain, safety Bristol-Myers Squibb
PROSPECT (NCT01322490) III mCRPC PROSTVAC-VF-TRICOM + GM-CSF vs PROSTVAC-VF-TRICOM + GM-CSF placebo vs Vector placebo + GM-CSF placebo OS, event-free progression Bavarian Nordic

ADPC indicates androgen-dependent prostate cancer; ADT, androgen-deprivation therapy; BF, biochemical failure; CRPC, castration-resistant prostate cancer;

DF, distant metastatic disease; GM-CSF, granulocyte-macrophage colony stimulating factor; PC, prostate cancer; PFS, progression-free survival; PSA, prostatespecific antigen; PSADT, PSA doubling time; OS, overall survival; RECIST, response evaluation criteria in solid tumors; RP, radical prostatectomy; XRT, radiotherapy.

PROSTVAC is a sequentially dosed combination of two poxviruses, Vaccinia and Fowlpox, each encoded with PSA plus TRICOM (three costimulatory molecules [B7.1, ICAM-1, and Lfa-3]). The first poxvirus is Vaccina-PSA-TRICOM; the second is Fowlpox-PSA-TRICOM.

Adapted from Gomella LG. Current and emerging immunotherapy strategies for prostate cancer. Presented at: 5th Annual Interdisciplinary Prostate Cancer Congress (IPCC); March 31, 2012; New York, NY.

Of these approaches, Gomella said in an interview that “we really have three that look like the hot things:” sipuleucel-T, ipilumumab, and PROSTVAC. “Sipuleucel-T being FDA-approved now for almost two years and being used clinically is a great thing to have for our patients,” he said. “Ipilimumab is showing very significant activity in prostate cancer so that one is very exciting. And lastly, the PROSTVAC-V TRICOM studies are going to be very interesting.”


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x